Table of Contents
<< Previous Issue | Feb 2024 (Vol: 2024, Issue: 2) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Merck & Co. to Acquire Harpoon Therapeutics for US$680 M
-
Novartis to Acquire MorphoSys for US$2.9 B to Expand Oncology Pipeline
-
Sanofi Acquires Rare Disease Developer Inhibrx for up to US$2.2 B
- Section: Research & Development
-
Novo Nordisk Signs US$252.6 M Deal with EraCal to Boost Obesity Portfolio